Renal Clearance of Fibroblast Growth Factor‐23 (FGF23) and its Fragments in Humans

Relative abundance of fibroblast growth factor‐23 (FGF23) measured by the C‐terminal (cFGF23, which measures both intact FGF23 and C‐terminal fragments) versus intact (iFGF23, measures only intact hormone) assays varies by kidney function in humans. Differential kidney clearance may explain this finding. We measured cFGF23 and iFGF23 in the aorta and bilateral renal veins of 162 patients with essential hypertension undergoing renal angiography. Using multivariable linear regression, we examined factors associated with aorta to renal vein reduction of FGF23 using both assays. Similar parameters and with addition of urine concentrations of cFGF23 and iFGF23 were measured in six Wistar rats. Mean ± standard deviation (SD) age was 54 ± 12 years, 54% were women, and mean creatinine clearance was 72 ± 48 mL/min/100 g. The human kidney reduced the concentrations of both cFGF23 (16% ± 12%) and iFGF23 (21% ± 16%), but reduction was higher for iFGF23. Greater kidney creatinine and PTH reductions were each independently associated with greater reductions of both cFGF23 and iFGF23. The greater kidney reduction of iFGF23 compared to cFGF23 appeared stable and consistent across the range of creatinine clearance evaluated. Kidney clearance was similar, and urine concentrations of both assays were low in the rat models, suggesting kidney metabolism of both cFGF23 and iFGF23. Renal reduction of iFGF23 is higher than that of creatinine and cFGF23. Our data suggest that FGF23 is metabolized by the kidney. However, the major cell types involved in metabolization of FGF23 requires future study. Kidney clearance of FGF23 does not explain differences in C‐terminal and intact moieties across the range of kidney function. © 2022 American Society for Bone and Mineral Research (ASBMR).

[1]  M. Wolf,et al.  FGF23 at the crossroads of phosphate, iron economy and erythropoiesis , 2019, Nature Reviews Nephrology.

[2]  David A. Drew,et al.  Performance of soluble Klotho assays in clinical samples of kidney disease , 2019, Clinical kidney journal.

[3]  Z. Qin,et al.  Fibroblast growth factor 23 as a predictor of cardiovascular and all-cause mortality in prospective studies. , 2017, Atherosclerosis.

[4]  D. Leaf,et al.  Fibroblast Growth Factor 23 Levels Associate with AKI and Death in Critical Illness. , 2017, Journal of the American Society of Nephrology : JASN.

[5]  C. Kovesdy,et al.  FGF23 from bench to bedside. , 2016, American journal of physiology. Renal physiology.

[6]  B. Kestenbaum,et al.  Renal Clearance of Mineral Metabolism Biomarkers. , 2016, Journal of the American Society of Nephrology : JASN.

[7]  M. Mace,et al.  Key role of the kidney in the regulation of fibroblast growth factor 23. , 2015, Kidney international.

[8]  M. Wolf,et al.  Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production , 2015, Kidney international.

[9]  M. Mohammadi,et al.  The demonstration of αKlotho deficiency in human chronic kidney disease with a novel synthetic antibody. , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[10]  Yunjun Xiao,et al.  FGF 23 and risk of all-cause mortality and cardiovascular events: a meta-analysis of prospective cohort studies. , 2014, International journal of cardiology.

[11]  B. Lanske,et al.  The kidney is the principal organ mediating klotho effects. , 2014, Journal of the American Society of Nephrology : JASN.

[12]  Leah R. Padgett,et al.  Genetic rescue of glycosylation-deficient Fgf23 in the Galnt3 knockout mouse. , 2014, Endocrinology.

[13]  J. Pankow,et al.  Fibroblast Growth Factor‐23 and Incident Coronary Heart Disease, Heart Failure, and Cardiovascular Mortality: The Atherosclerosis Risk In Communities Study , 2014, Journal of the American Heart Association.

[14]  J. Polak,et al.  Fibroblast Growth Factor-23 and Cardiovascular Disease in the General Population: The Multi-Ethnic Study of Atherosclerosis , 2014, Circulation. Heart failure.

[15]  D. Mellström,et al.  Fibroblast growth factor 23, mineral metabolism and mortality among elderly men (Swedish MrOs) , 2013, BMC Nephrology.

[16]  B. Kestenbaum,et al.  Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). , 2012, Journal of the American College of Cardiology.

[17]  Edward R. Smith,et al.  Biological variability of plasma intact and C-terminal FGF23 measurements. , 2012, The Journal of clinical endocrinology and metabolism.

[18]  Jason R. Stubbs,et al.  Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[19]  A. Go,et al.  FGF23 induces left ventricular hypertrophy. , 2011, The Journal of clinical investigation.

[20]  Jiang He,et al.  Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. , 2011, JAMA.

[21]  J. Silver,et al.  PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. , 2010, American journal of physiology. Renal physiology.

[22]  J. Silver,et al.  FGF23 and the parathyroid glands , 2010, Pediatric Nephrology.

[23]  M. Wolf,et al.  Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. , 2010, The Journal of clinical endocrinology and metabolism.

[24]  M. Razzaque,et al.  Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation , 2009, Proceedings of the National Academy of Sciences.

[25]  Hang Lee,et al.  Effects of hPTH(1‐34) Infusion on Circulating Serum Phosphate, 1,25‐Dihydroxyvitamin D, and FGF23 Levels in Healthy Men , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[26]  E. Farrow,et al.  Initial FGF23-mediated signaling occurs in the distal convoluted tubule. , 2009, Journal of the American Society of Nephrology : JASN.

[27]  P. Royston.  Multiple Imputation of Missing Values , 2004 .

[28]  S. Fukumoto,et al.  Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. , 2003, The New England journal of medicine.

[29]  J. V. van Engelshoven,et al.  Asymmetry of Renal Blood Flow in Patients With Moderate to Severe Hypertension , 2003, Hypertension.

[30]  J. V. van Engelshoven,et al.  Nitric oxide dependence of renal blood flow in patients with renal artery stenosis. , 2001, Journal of the American Society of Nephrology : JASN.

[31]  K. Hruska,et al.  The renal handling of parathyroid hormone. Role of peritubular uptake and glomerular filtration. , 1977, The Journal of clinical investigation.

[32]  S. Sidhu,et al.  Renal Production, Uptake, and Handling of Circulating αKlotho. , 2016, Journal of the American Society of Nephrology : JASN.

[33]  Lena Osterhagen,et al.  Multiple Imputation For Nonresponse In Surveys , 2016 .

[34]  E. Christensen,et al.  Megalin and cubilin in proximal tubule protein reabsorption: from experimental models to human disease. , 2016, Kidney international.

[35]  E. Ingelsson,et al.  Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community. , 2013, Kidney international.

[36]  D. Mellström,et al.  Fibroblast growth factor 23, mineral metabolism and mortality among elderly men , 2013 .

[37]  L. Quarles,et al.  Regulation and function of the FGF23/klotho endocrine pathways. , 2012, Physiological reviews.